The BET (bromodomain and extra-terminal) inhibitors have been shown to disrupt the interaction between BRD4 and the ASCL1 enhancer, resulting in the downregulation of ASCL1, and subsequent growth inhibition of SCLC cells37. Here, BRD4 is linked to small cell lung carcinoma.